Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 330

1.

The LRRK2 G2019S mutation in a series of Argentinean patients with Parkinson's disease: clinical and demographic characteristics.

Gatto EM, Parisi V, Converso DP, Poderoso JJ, Carreras MC, Martí-Massó JF, Paisán-Ruiz C.

Neurosci Lett. 2013 Mar 14;537:1-5. doi: 10.1016/j.neulet.2013.01.011. Epub 2013 Jan 20.

PMID:
23340200
2.

The LRRK2 G2019S mutation in Ashkenazi Jews with Parkinson disease: is there a gender effect?

Orr-Urtreger A, Shifrin C, Rozovski U, Rosner S, Bercovich D, Gurevich T, Yagev-More H, Bar-Shira A, Giladi N.

Neurology. 2007 Oct 16;69(16):1595-602.

PMID:
17938369
3.

Parkinson disease phenotype in Ashkenazi Jews with and without LRRK2 G2019S mutations.

Alcalay RN, Mirelman A, Saunders-Pullman R, Tang MX, Mejia Santana H, Raymond D, Roos E, Orbe-Reilly M, Gurevich T, Bar Shira A, Gana Weisz M, Yasinovsky K, Zalis M, Thaler A, Deik A, Barrett MJ, Cabassa J, Groves M, Hunt AL, Lubarr N, San Luciano M, Miravite J, Palmese C, Sachdev R, Sarva H, Severt L, Shanker V, Swan MC, Soto-Valencia J, Johannes B, Ortega R, Fahn S, Cote L, Waters C, Mazzoni P, Ford B, Louis E, Levy O, Rosado L, Ruiz D, Dorovski T, Pauciulo M, Nichols W, Orr-Urtreger A, Ozelius L, Clark L, Giladi N, Bressman S, Marder KS.

Mov Disord. 2013 Dec;28(14):1966-71. doi: 10.1002/mds.25647. Epub 2013 Oct 15.

4.

Motor phenotype of LRRK2 G2019S carriers in early-onset Parkinson disease.

Alcalay RN, Mejia-Santana H, Tang MX, Rosado L, Verbitsky M, Kisselev S, Ross BM, Louis ED, Comella CL, Colcher A, Jennings D, Nance MA, Bressman S, Scott WK, Tanner C, Mickel SF, Andrews HF, Waters CH, Fahn S, Cote LJ, Frucht SJ, Ford B, Rezak M, Novak K, Friedman JH, Pfeiffer R, Marsh L, Hiner B, Siderowf A, Caccappolo E, Ottman R, Clark LN, Marder KS.

Arch Neurol. 2009 Dec;66(12):1517-22. doi: 10.1001/archneurol.2009.267.

5.

The LRRK2 G2019S mutation as the cause of Parkinson's disease in Ashkenazi Jews.

Thaler A, Ash E, Gan-Or Z, Orr-Urtreger A, Giladi N.

J Neural Transm (Vienna). 2009 Nov;116(11):1473-82. doi: 10.1007/s00702-009-0303-0. Review.

PMID:
19756366
6.

Frequency of LRRK2 mutations in early- and late-onset Parkinson disease.

Clark LN, Wang Y, Karlins E, Saito L, Mejia-Santana H, Harris J, Louis ED, Cote LJ, Andrews H, Fahn S, Waters C, Ford B, Frucht S, Ottman R, Marder K.

Neurology. 2006 Nov 28;67(10):1786-91. Epub 2006 Oct 18.

PMID:
17050822
7.

LRRK2 mutations in Spanish patients with Parkinson disease: frequency, clinical features, and incomplete penetrance.

Gaig C, Ezquerra M, Marti MJ, Muñoz E, Valldeoriola F, Tolosa E.

Arch Neurol. 2006 Mar;63(3):377-82.

PMID:
16533964
8.

Dyskinesias in patients with Parkinson's disease: effect of the leucine-rich repeat kinase 2 (LRRK2) G2019S mutation.

Yahalom G, Kaplan N, Vituri A, Cohen OS, Inzelberg R, Kozlova E, Korczyn AD, Rosset S, Friedman E, Hassin-Baer S.

Parkinsonism Relat Disord. 2012 Nov;18(9):1039-41. doi: 10.1016/j.parkreldis.2012.05.014. Epub 2012 Jun 13.

PMID:
22703868
9.

LRRK2 mutations in Parkinson's disease: confirmation of a gender effect in the Italian population.

Cilia R, Siri C, Rusconi D, Allegra R, Ghiglietti A, Sacilotto G, Zini M, Zecchinelli AL, Asselta R, Duga S, Paganoni AM, Pezzoli G, Seia M, Goldwurm S.

Parkinsonism Relat Disord. 2014 Aug;20(8):911-4. doi: 10.1016/j.parkreldis.2014.04.016. Epub 2014 Apr 25.

10.

LRRK2 exon 41 mutations in sporadic Parkinson disease in Europeans.

Lesage S, Janin S, Lohmann E, Leutenegger AL, Leclere L, Viallet F, Pollak P, Durif F, Thobois S, Layet V, Vidailhet M, Agid Y, Dürr A, Brice A; French Parkinson's Disease Genetics Study Group., Bonnet AM, Borg M, Broussolle E, Damier P, Destée A, Martinez M, Penet C, Rasco O, Tison F, Tranchan C, Vérin M.

Arch Neurol. 2007 Mar;64(3):425-30.

PMID:
17353388
11.

LRRK2 G2019S mutation: frequency and haplotype data in South African Parkinson's disease patients.

Bardien S, Marsberg A, Keyser R, Lombard D, Lesage S, Brice A, Carr J.

J Neural Transm (Vienna). 2010 Jul;117(7):847-53. doi: 10.1007/s00702-010-0423-6. Epub 2010 Jun 11.

PMID:
20544233
12.

A common leucine-rich repeat kinase 2 gene mutation in familial and sporadic Parkinson's disease in Russia.

Illarioshkin SN, Shadrina MI, Slominsky PA, Bespalova EV, Zagorovskaya TB, Bagyeva GKh, Markova ED, Limborska SA, Ivanova-Smolenskaya IA.

Eur J Neurol. 2007 Apr;14(4):413-7.

PMID:
17388990
13.

Higher frequency of certain cancers in LRRK2 G2019S mutation carriers with Parkinson disease: a pooled analysis.

Agalliu I, San Luciano M, Mirelman A, Giladi N, Waro B, Aasly J, Inzelberg R, Hassin-Baer S, Friedman E, Ruiz-Martinez J, Marti-Masso JF, Orr-Urtreger A, Bressman S, Saunders-Pullman R.

JAMA Neurol. 2015 Jan;72(1):58-65. doi: 10.1001/jamaneurol.2014.1973.

14.

The leucine rich repeat kinase 2 (LRRK2) G2019S substitution mutation. Association with Parkinson disease, malignant melanoma and prevalence in ethnic groups in Israel.

Hassin-Baer S, Laitman Y, Azizi E, Molchadski I, Galore-Haskel G, Barak F, Cohen OS, Friedman E.

J Neurol. 2009 Mar;256(3):483-7. doi: 10.1007/s00415-009-0117-x. Epub 2009 Mar 24.

PMID:
19412725
15.

Motor progression of Parkinson's disease with the leucine-rich repeat kinase 2 G2019S mutation.

Yahalom G, Orlev Y, Cohen OS, Kozlova E, Friedman E, Inzelberg R, Hassin-Baer S.

Mov Disord. 2014 Jul;29(8):1057-60. doi: 10.1002/mds.25931. Epub 2014 Jun 5.

PMID:
24903616
16.

Age-specific penetrance of LRRK2 G2019S in the Michael J. Fox Ashkenazi Jewish LRRK2 Consortium.

Marder K, Wang Y, Alcalay RN, Mejia-Santana H, Tang MX, Lee A, Raymond D, Mirelman A, Saunders-Pullman R, Clark L, Ozelius L, Orr-Urtreger A, Giladi N, Bressman S; LRRK2 Ashkenazi Jewish Consortium..

Neurology. 2015 Jul 7;85(1):89-95. doi: 10.1212/WNL.0000000000001708. Epub 2015 Jun 10.

17.

LRRK2 G2019S and R1441G mutations associated with Parkinson's disease are common in the Basque Country, but relative prevalence is determined by ethnicity.

Gorostidi A, Ruiz-Martínez J, Lopez de Munain A, Alzualde A, Martí Massó JF.

Neurogenetics. 2009 Apr;10(2):157-9. doi: 10.1007/s10048-008-0162-0. Epub 2008 Nov 20.

PMID:
19020907
18.

High frequency and reduced penetrance of LRRK2 G2019S mutation among Parkinson's disease patients in Cantabria (Spain).

Sierra M, González-Aramburu I, Sánchez-Juan P, Sánchez-Quintana C, Polo JM, Berciano J, Combarros O, Infante J.

Mov Disord. 2011 Nov;26(13):2343-6. doi: 10.1002/mds.23965. Epub 2011 Sep 27.

PMID:
21954089
19.

Genetic analysis of LRRK2 mutations in patients with Parkinson disease.

Deng H, Le W, Guo Y, Hunter CB, Xie W, Huang M, Jankovic J.

J Neurol Sci. 2006 Dec 21;251(1-2):102-6. Epub 2006 Nov 9.

PMID:
17097110
20.

The LRRK2 G2019S mutation status does not affect the outcome of subthalamic stimulation in patients with Parkinson's disease.

Greenbaum L, Israeli-Korn SD, Cohen OS, Elincx-Benizri S, Yahalom G, Kozlova E, Strauss H, Molshatzki N, Inzelberg R, Spiegelmann R, Israel Z, Hassin-Baer S.

Parkinsonism Relat Disord. 2013 Nov;19(11):1053-6. doi: 10.1016/j.parkreldis.2013.07.005. Epub 2013 Aug 6.

PMID:
23932063

Supplemental Content

Support Center